MedTrace Logo

Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis

NCT01237119 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2016-03-23

No results posted yet for this study

Summary

The purpose of this study is to investigate whether 48 weeks treatment with once-daily injections of liraglutide improves liver disease (liver fat, inflammation and scarring) and related metabolic parameters in overweight patients with nonalcoholic steatohepatitis, enough to warrant further investigation.

Conditions

Interventions

DRUG

Liraglutide

1.8 mg once daily, subcutaneous injection

OTHER

Liraglutide-placebo

1.8 mg once-daily, subcutaneous injection

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • University of Birmingham

    lead OTHER

Principal Investigators

  • Philip N Newsome, FRCPE PhD · Centre for liver research, University of Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01237119 on ClinicalTrials.gov